{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High+Dose+Drug+A&page=18",
    "query": {
      "intervention": "High Dose Drug A",
      "page": 18
    },
    "page_size": 10
  },
  "pagination": {
    "page": 18,
    "page_size": 10,
    "total_count": 1666,
    "total_pages": 167,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High+Dose+Drug+A&page=19&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High+Dose+Drug+A&page=17&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T12:05:31.982Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04243785",
      "title": "A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "BTX-A51",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Edgewood Oncology Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2020-01-06",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2024-03-20",
      "last_synced_at": "2026-11-15T12:05:31.982Z",
      "location_count": 3,
      "location_summary": "Duarte, California • New York, New York • Houston, Texas",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04243785"
    },
    {
      "nct_id": "NCT05220397",
      "title": "Janssen Ad26.CoV2.S Vaccine Booster in Kidney Transplant Recipients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Kidney Transplant Recipient"
      ],
      "interventions": [
        {
          "name": "Janssen Ad26.CoV2.S Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Reduction in Immunosuppression Medication",
          "type": "OTHER"
        },
        {
          "name": "Maintenance in Immunosuppression Medication",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Mark Stegall",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 468,
      "start_date": "2022-04-11",
      "completion_date": "2025-02-28",
      "has_results": true,
      "last_update_posted_date": "2025-09-15",
      "last_synced_at": "2026-11-15T12:05:31.982Z",
      "location_count": 3,
      "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05220397"
    },
    {
      "nct_id": "NCT05543252",
      "title": "An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "Minzasolmin (UCB0599)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UCB Biopharma SRL",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "78 Years",
        "sex": "ALL",
        "summary": "40 Years to 78 Years"
      },
      "enrollment_count": 428,
      "start_date": "2022-08-29",
      "completion_date": "2025-03-25",
      "has_results": true,
      "last_update_posted_date": "2026-04-02",
      "last_synced_at": "2026-11-15T12:05:31.982Z",
      "location_count": 41,
      "location_summary": "Phoenix, Arizona • Fountain Valley, California • Fresno, California + 35 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05543252"
    },
    {
      "nct_id": "NCT00688597",
      "title": "Study to Evaluate the Safety of AT2220 (Duvoglustat) in Pompe Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pompe Disease"
      ],
      "interventions": [
        {
          "name": "Duvoglustat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amicus Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 3,
      "start_date": "2008-12-08",
      "completion_date": "2009-12-14",
      "has_results": true,
      "last_update_posted_date": "2025-09-11",
      "last_synced_at": "2026-11-15T12:05:31.982Z",
      "location_count": 1,
      "location_summary": "Decatur, Georgia",
      "locations": [
        {
          "city": "Decatur",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00688597"
    },
    {
      "nct_id": "NCT01718197",
      "title": "Severe Asthma Research Program (SARP)- San Francisco Clinical Site",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Asthma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 151,
      "start_date": "2012-11",
      "completion_date": "2021-03-01",
      "has_results": false,
      "last_update_posted_date": "2025-07-31",
      "last_synced_at": "2026-11-15T12:05:31.982Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01718197"
    },
    {
      "nct_id": "NCT04907968",
      "title": "Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Platinum-sensitive Ovarian Cancer (UPGRADE-A)"
      ],
      "interventions": [
        {
          "name": "XMT-1536 (Upifitamab Rilsodotin)",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mersana Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 31,
      "start_date": "2021-06-11",
      "completion_date": "2023-10-03",
      "has_results": false,
      "last_update_posted_date": "2023-10-10",
      "last_synced_at": "2026-11-15T12:05:31.982Z",
      "location_count": 1,
      "location_summary": "Grand Rapids, Michigan",
      "locations": [
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04907968"
    },
    {
      "nct_id": "NCT03507374",
      "title": "PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Stroke",
        "Intracranial Atherosclerosis",
        "Intraplaque Hemorrhage"
      ],
      "interventions": [
        {
          "name": "Alirocumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2018-10-30",
      "completion_date": "2020-04-17",
      "has_results": false,
      "last_update_posted_date": "2020-04-21",
      "last_synced_at": "2026-11-15T12:05:31.982Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03507374"
    },
    {
      "nct_id": "NCT02341274",
      "title": "Effects of Altered Formulation on the Bioequivalence of Tacrolimus in Healthy Female and Male Volunteeers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bioequivalence"
      ],
      "interventions": [
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 24,
      "start_date": "2016-11-11",
      "completion_date": "2018-01-20",
      "has_results": false,
      "last_update_posted_date": "2023-04-07",
      "last_synced_at": "2026-11-15T12:05:31.982Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02341274"
    },
    {
      "nct_id": "NCT02693535",
      "title": "TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma, Non-Hodgkin",
        "Multiple Myeloma",
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Sunitinib (CLOSED TO ENROLLMENT)",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT)",
          "type": "DRUG"
        },
        {
          "name": "Vemurafenib and Cobimetinib (CLOSED TO ENROLLMENT)",
          "type": "DRUG"
        },
        {
          "name": "Olaparib (CLOSED TO ENROLLMENT)",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab and Ipilimumab (CLOSED TO ENROLLMENT)",
          "type": "DRUG"
        },
        {
          "name": "Abemaciclib (CLOSED TO ENROLLMENT)",
          "type": "DRUG"
        },
        {
          "name": "Talazoparib (CLOSED TO ENROLLMENT)",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab and Talazoparib (CLOSED TO ENROLLMENT)",
          "type": "DRUG"
        },
        {
          "name": "Tucatinib plus Trastuzumab Subcutaneous (SC) (CLOSED TO ENROLLMENT)",
          "type": "DRUG"
        },
        {
          "name": "Futibatinib",
          "type": "DRUG"
        },
        {
          "name": "Dabrafenib plus Trametinib",
          "type": "DRUG"
        },
        {
          "name": "Fam-Trastuzumab Deruxtecan-Nxki (TDxD)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "American Society of Clinical Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 4200,
      "start_date": "2016-03-14",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-22",
      "last_synced_at": "2026-11-15T12:05:31.982Z",
      "location_count": 174,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Auburn, California + 137 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Auburn",
          "state": "California"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02693535"
    },
    {
      "nct_id": "NCT01973517",
      "title": "High-Field MRI Iron-Based Contrast-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Feraheme",
          "type": "DRUG"
        },
        {
          "name": "Gadolinium-based contrast",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2014-04",
      "completion_date": "2018-09",
      "has_results": false,
      "last_update_posted_date": "2018-09-10",
      "last_synced_at": "2026-11-15T12:05:31.982Z",
      "location_count": 2,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01973517"
    }
  ]
}